HomeCompareDTXMF vs ARCC

DTXMF vs ARCC: Dividend Comparison 2026

DTXMF yields 2099.96% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTXMF wins by $15665483173.77M in total portfolio value
10 years
DTXMF
DTXMF
● Live price
2099.96%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15665483173.80M
Annual income
$14,323,699,878,768,094.00
Full DTXMF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — DTXMF vs ARCC

📍 DTXMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTXMFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTXMF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DTXMF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTXMF
Annual income on $10K today (after 15% tax)
$178,496.43/yr
After 10yr DRIP, annual income (after tax)
$12,175,144,896,952,880.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, DTXMF beats the other by $12,175,144,896,952,880.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTXMF + ARCC for your $10,000?

DTXMF: 50%ARCC: 50%
100% ARCC50/50100% DTXMF
Portfolio after 10yr
$7832741586.91M
Annual income
$7,161,849,939,384,048.00/yr
Blended yield
91.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

DTXMF
No analyst data
Altman Z
8.7
Piotroski
2/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTXMF buys
0
ARCC buys
0
No recent congressional trades found for DTXMF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTXMFARCC
Forward yield2099.96%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$15665483173.80M$24.5K
Annual income after 10y$14,323,699,878,768,094.00$1.16
Total dividends collected$15570599104.15M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: DTXMF vs ARCC ($10,000, DRIP)

YearDTXMF PortfolioDTXMF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$220,696$209,995.80$11,381$541.15+$209.3KDTXMF
2$4,567,471$4,331,326.27$12,621$284.08+$4.55MDTXMF
3$88,663,041$83,775,847.71$13,827$145.31+$88.65MDTXMF
4$1,614,723,560$1,519,854,105.24$15,062$73.43+$1614.71MDTXMF
5$27,596,399,156$25,868,644,947.25$16,364$36.89+$27596.38MDTXMF
6$442,712,758,641$413,184,611,544.43$17,757$18.49+$442712.74MDTXMF
7$6,668,541,041,184$6,194,838,389,437.68$19,258$9.25+$6668541.02MDTXMF
8$94,343,071,214,447$87,207,732,300,379.95$20,880$4.63+$94343071.19MDTXMF
9$1,254,003,079,467,744$1,153,055,993,268,286.20$22,636$2.32+$1254003079.45MDTXMF
10$15,665,483,173,798,580$14,323,699,878,768,094.00$24,539$1.16+$15665483173.77MDTXMF

DTXMF vs ARCC: Complete Analysis 2026

DTXMFStock

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.

Full DTXMF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this DTXMF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTXMF vs SCHDDTXMF vs JEPIDTXMF vs ODTXMF vs KODTXMF vs MAINDTXMF vs HTGCDTXMF vs GBDCDTXMF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.